Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjan Chakrabarti

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Expert Opinion on Therapeutic Targets|February 25, 2009
Pharmacotherapy of obesity: emerging drugs and targetsRanjan Chakrabarti
The Indian Journal of Medical Research|May 15, 2007
The role of AMP kinase in diabetesParimal Misra, Ranjan Chakrabarti
Cardiovascular & Hematological Agents in Medicinal Chemistry|July 17, 2007
Advances in antithrombotic agentsRanjan Chakrabarti, Saibal Kumar Das
Recent Patents on Cardiovascular Drug Discovery|January 29, 2008
Role of PPAR in cardiovascular diseasesSaibal Kumar Das, Ranjan Chakrabarti
Mini Reviews in Medicinal Chemistry|November 26, 2005
Non-insulin dependent diabetes mellitus: present therapies and new drug targetsSaibal Kumar Das, Ranjan Chakrabarti
Current Medicinal Chemistry|May 25, 2006
Antiobesity therapy: emerging drugs and targetsSaibal Kumar Das, Ranjan Chakrabarti
Human Vaccines & Immunotherapeutics|July 1, 2021
Building trust in the quality of vaccinesFouad Atouf, Ranjan Chakrabarti, Annu Uppal
Journal of Pharmaceutical Innovation|December 1, 2021
Biopharmaceutical Industry Capability Building in India: Report from a SymposiumAnnu Uppal, Ranjan Chakrabarti, Narendra Chirmule, et al.
European Journal of Medicinal Chemistry|December 26, 2006
Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activatorsRakesh Kumar, Uma Ramachandran, Suryaprakash Raichur, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agentsGurram R Madhavan, Vadla Balraju, Bejugam Mallesham, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Expert Opinion on Therapeutic Targets|February 25, 2009
Pharmacotherapy of obesity: emerging drugs and targetsRanjan Chakrabarti
The Indian Journal of Medical Research|May 15, 2007
The role of AMP kinase in diabetesParimal Misra, Ranjan Chakrabarti
Cardiovascular & Hematological Agents in Medicinal Chemistry|July 17, 2007
Advances in antithrombotic agentsRanjan Chakrabarti, Saibal Kumar Das
Recent Patents on Cardiovascular Drug Discovery|January 29, 2008
Role of PPAR in cardiovascular diseasesSaibal Kumar Das, Ranjan Chakrabarti
Mini Reviews in Medicinal Chemistry|November 26, 2005
Non-insulin dependent diabetes mellitus: present therapies and new drug targetsSaibal Kumar Das, Ranjan Chakrabarti
Current Medicinal Chemistry|May 25, 2006
Antiobesity therapy: emerging drugs and targetsSaibal Kumar Das, Ranjan Chakrabarti
Human Vaccines & Immunotherapeutics|July 1, 2021
Building trust in the quality of vaccinesFouad Atouf, Ranjan Chakrabarti, Annu Uppal
Journal of Pharmaceutical Innovation|December 1, 2021
Biopharmaceutical Industry Capability Building in India: Report from a SymposiumAnnu Uppal, Ranjan Chakrabarti, Narendra Chirmule, et al.
European Journal of Medicinal Chemistry|December 26, 2006
Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activatorsRakesh Kumar, Uma Ramachandran, Suryaprakash Raichur, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agentsGurram R Madhavan, Vadla Balraju, Bejugam Mallesham, et al.
Pageof 3